Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Skyrizi Auto-Doser Peak Sales Put at 30-Plus Billion Yen, Mounjaro Not on Roster: November Listing
The Central Social Insurance Medical Council (Chuikyo) on November 9 approved a throng of medicines for their reimbursement listing on November 16, with a subcutaneous auto-doser version of Skyrizi (risankizumab) carrying the largest peak sales outlook of over 30 billion…
To read the full story
Related Article
- AbbVie Rolls Out Skyrizi Auto-Doser in Japan
February 14, 2023
- Sanofi Launches Cablivi in Japan for Acquired TTP
December 26, 2022
- Taisho’s Nanozora, 1st Nanobody Agent in Japan, Now Available
December 2, 2022
- Sotyktu, Spevigo, Fintepla, Koselugo, and More Now Available in Japan
November 17, 2022
REGULATORY
- Japan to Finalize 1st ALS Trial Guidelines This Year to Spur Global Development
May 13, 2026
- Biosimilar Efficacy Trials Can Be Waived under Certain Conditions: MHLW
May 13, 2026
- LDP Lawmakers’ League Eyes Broader Push for Domestic API Production
May 13, 2026
- AstraZeneca’s Oral SERD, MSD RSV Antibody Up for Japan Panel Review on May 25
May 12, 2026
- Daiichi Sankyo Wins Japan Approval for MMR Vaccine Mimrit
May 12, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…